Oral Antidiabetic Drugs Market by Drugs Class Category (Sulfonylureas, Meglitinides, Biguanides and Alpha-glucosidase inhibitors) for Type 2 Diabetes mellitus - Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 – 2022

Description

The report covers forecast and analysis for the oral antidiabetic drugs market on a global and regional level. The study provides historic data of 2016 along with a forecast from 2017 to 2022 based on revenue (USD billion). The study includes drivers and restraints of the oral antidiabetic drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the oral antidiabetic drugs market on a global level.

In order to give the users a comprehensive view of the Oral antidiabetic drugs market, we have included a detailed competitive scenario and product portfolio of key vendors. To understand the competitive landscape in the market, an analysis of Porter’s five forces model for the oral antidiabetic drugs market has also been included. The study encompasses a market attractiveness analysis, wherein the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The study provides a decisive view on the oral antidiabetic drugs market by segmenting the market based on drugs class and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2017 to 2022. The drugs class segmentation includes sulfonylureas, meglitinides, biguanides, alpha-glucosidase inhibitors and others. The meglitinides class is further segmented into repaglinide and nateglinide. The regional segmentation includes the current and forecast demand for North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. These regions are further sub-segmented into U.S., Canada, China, Japan, and Brazil.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global oral antidiabetic drugs market include Eli Lilly, Abbott, Biocon, Sanofi, Sunpharma, Novartis, Novo Nordisk, Merck and Pfizer.

This report segments the global oral antidiabetic drugs Market as follows:

Global Oral Antidiabetic Drugs Market: Drugs Class Analysis

• Sulfonylureas
  • Glimepiride
  •  Gliclazide
  •  Glyburide
  •  Others
• Meglitinides

• Repaglinide
• Nateglinide

• Biguanides
  • Metformin
  •  Others
• Alpha-glucosidase inhibitors
  • Acarbose
  •  Voglibose
  •  Others
• Others

Global Oral Antidiabetic Drugs Market: Regional Segment Analysis

• North America
  • U.S.
  • Canada
• Europe
  • Asia Pacific
  • China
  • Japan
  • Rest of Asia Pacific
• Latin America
  • Brazil
• Middle East and Africa

Table Of Content

• Chapter 1. Introduction
  • 1.1. Report Description And Scope
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology
• Chapter 2. Executive Summary
  • 2.1. Global Oral Anti-Diabetic Market, 2016 - 2022 (USD Billion)
  • 2.2. Global Oral Anti-Diabetic Market: Snapshot
• Chapter 3. Oral Anti-Diabetic – Market Dynamics
  • 3.1. Introduction
  • 3.2. Value Chain Analysis
  • 3.3. Market Drivers
    • 3.3.1. Global Oral Anti-Diabetic Market Drivers: Impact Analysis
    • 3.3.2. Rising Prevalence Of Diabetes Mellitus
    • 3.3.3. Increase In Obesity
  • 3.4. Market Restraints
    • 3.4.1. Global Oral Anti-Diabetic Market Restraints: Impact Analysis
    • 3.4.2. High Cost of Drugs
  • 3.5. Opportunities
    • 3.5.1. Market Strength
  • 3.6. Porter’s Five Forces Analysis
    • 3.6.1. Bargaining Power Of Suppliers
    • 3.6.2. Bargaining Power Of Buyers
    • 3.6.3. Threat From New Entrants
    • 3.6.4. Threat From New Substitutes
    • 3.6.5. Degree Of Competition
  • 3.7. Market Attractiveness Analysis
    • 3.7.1. Market Attractiveness Analysis, By Drug Class Segment
    • 3.7.2. Market Attractiveness Analysis, By Regional Segment
• Chapter 4. Global Oral Anti-Diabetic Market – Competitive Landscape
  • 4.1. Company Market Share, 2016 (Subject To Data Availability)
  • 4.2. Strategic Development
    • 4.2.1. Acquisitions & Mergers
    • 4.2.2. New Type Launch
    • 4.2.3. Agreements, Partnerships, Collaborations And Joint Ventures
    • 4.2.4. Research And Development, Regional Expansion
  • 4.3. Type Portfolio
• Chapter 5. Global Oral Anti-Diabetic Market – Drug Class Analysis
  • 5.1. Global Oral Anti-Diabetic Market: Drug Class Segment Overview
    • 5.1.1. Global Oral Anti-Diabetic Market Revenue Share, By Drug Class, 2016 And 2022
  • 5.2. Sulfonylureas
    • 5.2.1. Global Sulfonylureas Market, 2016 – 2022 (USD Billion)
    • 5.2.2. Glimepiride
      • 5.2.2.1. Glimepiride Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
    • 5.2.3. Gliclazide
      • 5.2.3.1. Gliclazide Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
    • 5.2.4. Glyburide
      • 5.2.4.1. Glyburide Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
    • 5.2.5. Others
      • 5.2.5.1. Others Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
  • 5.3. Meglitinides
    • 5.3.1. Global Meglitinides Market, 2016 – 2022 (USD Billion)
    • 5.3.2. Repaglinide
      • 5.3.2.1. Repaglinide Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
    • 5.3.3. Nateglinide
      • 5.3.3.1. Nateglinide Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
  • 5.4. Biguanides
    • 5.4.1. Global Biguanides Market, 2016 – 2022 (USD Billion)
    • 5.4.2. Metformin
      • 5.4.2.1. Metformin Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
    • 5.4.3. Others
      • 5.4.3.1. Others Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
    • 5.5. Alpha-glucosidase inhibitors
      • 5.5.1. Global Alpha-glucosidase inhibitors Market, 2016 – 2022 (USD Billion)
      • 5.5.2. Acarbose
        • 5.5.2.1. Acarbose Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
      • 5.5.3. Voglibose
        • 5.5.3.1. Voglibose Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
      • 5.5.4. Others
        • 5.5.4.1. Others Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
• Chapter 6. Global Oral Anti-Diabetic Market – Regional Segment Analysis
  • 6.1. Global Oral Anti-Diabetic Market: Regional Overview
    • 6.1.1. Global Oral Anti-Diabetic Market Revenue Share, By Region, 2016 And 2022
  • 6.2. North America
    • 6.2.1. North America Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022, (USD Billion)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
    • 6.2.3. Canada
      • 6.2.3.1. Canada Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
  • 6.3. Europe
    • 6.3.1. Europe Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
    • 6.3.2. Germany
      • 6.3.2.1. Germany Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022, (USD Billion)
    • 6.3.3. France
      • 6.3.3.1. France Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022, (USD Billion)
    • 6.3.4. U.K.
      • 6.3.4.1. U.K. Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
    • 6.4.2. China
      • 6.4.2.1. China Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
    • 6.4.3. Japan
      • 6.4.3.1. Japan Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
    • 6.4.4. India
      • 6.4.4.1. India Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
  • 6.5. Latin America
    • 6.5.1. Latin America Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
  • 6.6. Middle East And Africa
    • 6.6.1. Middle East And Africa Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
• Chapter 7. Company Profile
  • 7.1. Abbott Laboratories
    • 7.1.1. Overview
    • 7.1.2. Financials
    • 7.1.3. Product Portfolio
    • 7.1.4. Business Strategy
    • 7.1.5. Recent Developments
  • 7.2. Biocon, Ltd
    • 7.2.1. Overview
    • 7.2.2. Financials
    • 7.2.3. Product Portfolio
    • 7.2.4. Business Strategy
    • 7.2.5. Recent Developments
  • 7.3. Eli Lilly and Company
    • 7.3.1. Overview
    • 7.3.2. Financials
    • 7.3.3. Product Portfolio
    • 7.3.4. Business Strategy
    • 7.3.5. Recent Developments
  • 7.4. Sun Pharma Industries, Ltd.
    • 7.4.1. Overview
    • 7.4.2. Financials
    • 7.4.3. Product Portfolio
    • 7.4.4. Business Strategy
    • 7.4.5. Recent Developments
  • 7.5. Novo Nordisk A/S
    • 7.5.1. Overview
    • 7.5.2. Financials
    • 7.5.3. Product Portfolio
    • 7.5.4. Business Strategy
    • 7.5.5. Recent Developments
  • 7.6. Pfizer
    • 7.6.1. Overview
    • 7.6.2. Financials
    • 7.6.3. Product Portfolio
    • 7.6.4. Business Strategy
    • 7.6.5. Recent Developments
  • 7.7. Sanofi
    • 7.7.1. Overview
    • 7.7.2. Financials
    • 7.7.3. Product Portfolio
    • 7.7.4. Business Strategy
    • 7.7.5. Recent Developments
  • 7.8. Novartis
    • 7.8.1. Overview
    • 7.8.2. Financials
    • 7.8.3. Product Portfolio
    • 7.8.4. Business Strategy
    • 7.8.5. Recent Developments
  • 7.9. Merck Group
    • 7.9.1. Overview
    • 7.9.2. Financials
    • 7.9.3. Product Portfolio
    • 7.9.4. Business Strategy
    • 7.9.5. Recent Development

Methodology

This report is based on in-depth qualitative and quantitative analyses of the global Oral Anti-diabetic Drugs market. Zion Research has collected and analyzed key data belong to the global Oral Anti-diabetic Drugs market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.

The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.

Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in from the sales of Oral Anti-diabetic Drugs across the world has been calculated through primary and secondary research.

Zion Market Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc. 

For this study, Zion Market Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in the validation of findings from secondary research and to understand key trends in the Oral Anti-diabetic Drugs industry. Primary research makes up the major source of data collection and validation.   

Primary Research

We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:

• Provides firsthand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
• Helps in validating and strengthening the secondary research findings
• Further, develops the analysis team’s expertise and market understanding
• Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

Participants who typically participate in such a process include, but are not limited to:

• Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
• Purchasing managers, technical personnel, distributors and resellers
• Outside experts: Investment bankers, valuation experts and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

Secondary Research

Secondary research sources that are typically referred to include, but are not limited to:

• Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
• IDC and other relevant magazines
• Internal and external proprietary databases, and relevant patent and regulatory databases
• National government documents, statistical databases and market reports

News articles, press releases and webcasts specific to companies operating in the market

Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Oral Anti-diabetic Drugs market.

Models

Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:

• Demographic data: Population split by segments
• Macroeconomic indicators: GDP, PPP, Per Capita Income, etc.
• Industry indicators: Expenditure, technology stage and infrastructure, sector growth and facilities
• Data is then cross-checked by an expert panel.

Free Analysis

Diabetes is a group of metabolic disorder characterized by the presence of high blood glucose level than normal level in an individual. The rise of blood glucose is due to inadequate insulin production, or because the body's cells do not respond properly to insulin. Diabetes is broadly characterized into two types: Insulin-dependent diabetes mellitus (type 1) and Non-insulin dependent diabetes mellitus (type 2). Various initial symptoms associated with diabetes include increasing thirst, frequent urination, fatigue, weight and muscle loss, delayed wound healing and blurred vision.

The global rise in oral anti-diabetic drug market is mainly due to increase in the prevalence of diabetic patient across the globe. According to WHO, the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. This rise is continuously seen in developing countries like India and China. Moreover, the factors which are responsible for increasing numbers of the diabetic population globally include sedentary lifestyles, obesity, the rise in geriatric populations and poor healthcare services. However, a high cost of the drug is expected to restraint the growth of global oral anti-diabetic drug market. Nonetheless, huge market strength and untapped market of Asia Pacific and Africa market considered as a major opportunity for upcoming manufacturers of global oral anti-diabetic drug markets.

Based on the class of drug, the global oral anti-diabetic drug market is segmented into five types: sulfonylureas, meglitinides, biguanides, alpha-glucosidase inhibitors and others. Sulphonylureas segment of oral anti-diabetic drug market accounted for the largest market share in 2016 followed by biguanides derivatives. In 2016, Sulphonylureas accounted for about 37% share of the total oral anti-diabetic market. The growth is attributed due to the availability of low cost of drugs under this segment. A drug under this category includes glimepiride, gliclazide, glyburide and others. Whereas, Biguanides derivatives account for the second largest shares in the total oral anti-diabetic market followed by alpha-glucosidase inhibitors. Metformin is a biguanide class which is most preferred oral anti-diabetics drug currently prescribed by a physician for the treatment of Type 2 diabetes mellitus.

Key market players of oral anti-diabetic drug market include Eli Lilly, Abbott, Biocon, Sanofi, Sunpharma, Novartis, Novo Nordisk, Merck and Pfizer.